Tumor miR-622 is a predictive biomarker of response to maintenance PARP inhibitor olaparib after platinum-based chemotherapy in patients with advanced/metastatic endometrial cancer: ancillary analysis of UTOLA GINECO trial.

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Nicolas Vigneron, François Cherifi, Raphaël Leman, Alexia Laplanche, Mégane Vernon, Sarah Burton, François Christy, Olivier Trédan, Benoît You, Manuel Jorge Rodrigues, Laurence Gladieff, Sophie Abadie-Lacoutoisie
+8 more P. Fournel, Guillaume Beinse, Jérôme Alexandre, Pierre‐Alexandre Just, Laurent Poulain, Roman Rouzier, Florence Joly, Christophe Denoyelle
DOI: 10.1016/j.ijgc.2025.103484
Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments BRCA gene mutations in cancer

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103484–103484
Publication date
1 February 2026
Language
EN